In Brief: Novo Nordisk's Norditropin
Executive Summary
Novo Nordisk's Norditropin: Marketing may begin 21 days following a Feb. 26 D.C. federal appeals court decision to overturn a preliminary injunction granted to Genentech in June against the sale of the human growth hormone. Genentech filed a patent infringement suit against Novo Nordisk and Bio-Technology General (Biotropin) in December after the ITC dismissed the Protropin/Nutropin manufacturer's complaint seeking to bar importation of the companies' hGH products. The same appellate court will decide on Genentech's appeal of the ITC decision. The patent dispute will continue as the case goes to trial in Brooklyn federal court later this year or early next year...